Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surgery

Last updated: August 5, 2024
Sponsor: Uji Takeda Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

N/A

Treatment

Ampicillin

Clinical Study ID

NCT06368102
R6-03
  • Ages > 20
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to determine the incidence of surgical site infection (SSIs) after third molar surgery for different duration of intravenous ampicillin administration.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Minimum age of 20 years

  • American Society of Anesthesiologists (ASA) physical status of 1

  • Planned extraction of bilateral mandibular third molar with the necessity of boneremoval based on panoramic radiography in an inpatient setting under IV sedation

  • Agreement to follow the study protocol

Exclusion

Exclusion Criteria:

  • Pregnancy or suspicion of pregnancy

  • Allergy and/or contraindication to ampicillin

  • History of a known SSI risk factors, such as diabetes, steroid or immunosuppressantuse, and endocarditis

  • Receiving any antibiotic therapy

  • Active infection of the third molars with pus, edema, and trismus

Study Design

Total Participants: 70
Treatment Group(s): 1
Primary Treatment: Ampicillin
Phase: 4
Study Start date:
May 02, 2024
Estimated Completion Date:
August 31, 2025

Study Description

In recent years, the increase in drug-resistant bacteria and associated infections has become one of the major issues in the international community as adverse events associated with the inappropriate use of antimicrobial agents. Although the frequency and percentage of inappropriate use is currently unknown, it has been shown that at least 30% of antimicrobials prescribed in the U.S. are inappropriately used. If no action is taken against inappropriate antimicrobial use, it is estimated that 10 million people will die annually worldwide from drug-resistant organisms by 2050, with an estimated 4.9 million deaths related to drug-resistant organisms and 1.2 million deaths due to drug-resistant organisms already estimated for 2019. In addition, while the development of new antimicrobial agents has declined since the 1980s, the threat of new drug-resistant organisms, especially in hospitals, has increased, and if antimicrobial agents are not used appropriately, there is concern that there will be no effective antimicrobial agents available to treat infections in the future. It is important to avoid such situations by using antimicrobial agents, which are a limited resource, appropriately at this stage, and appropriate use of antimicrobial agents is necessary to prevent drug resistance (Antimicrobial Resistance: AMR).

Third molar extraction is the most commonly performed procedure in oral and maxillofacial surgery. One of the main complications after third molar extractions is surgical site infection (SSIs), which is reported to manifest as swelling, pain, abscess, and fever. According to a Cochrane review of randomized controlled trials, the risk of SSIs after third molar extraction in physically fit young patients is about 10%, but in patients with low immunity before extraction, the risk increases up to 25%. Prophylactic administration of antimicrobial agents has an important role in preventing SSIs. However, the efficacy of antimicrobial prophylaxis against SSIs in third molar extractions is controversial. While some studies have reported that antimicrobials are effective in preventing SSIs after third molar extraction, others have reported that they are not.

Guidelines for third molar extraction vary widely in the duration of antimicrobial administration (e.g., Japanese guidelines state a single dose to within 48 hours). In clinical practice, the final decision lies with the surgeon, but this difference in dosing period is a source of confusion. If the duration of administration could be shortened without increasing SSIs, it would contribute to the current presentation of AMR. Therefore, the purpose of this study is to examine the effect of different durations and doses of penicillins, which are considered first-line drugs after third molar surgery, on the prevention of SSIs.

Connect with a study center

  • Uji Takeda Hospital

    Uji,
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.